Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Inicie sesión o únase ahora para utilizar esta función

Not Yet Recruiting

Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA) - CV010-031

Actualizada: 05 December, 2018   |   ClinicalTrials.gov

Imprimir Resumen

¿ESTÁ CONSIDERANDO PARTICIPAR EN ESTE ESTUDIO?
Imprima esta página y la guía del estudio para poder hablar mejor con su médico.
Use la guía de estudios para explorar el proceso de participación en un estudio clínico. Comprenda qué factores clave debe considerar antes de decidirse y piense preguntas para hacerle a su equipo de atención médica.
Imprima esta página CV010-031
Descargar guía

SELECCIONAR IDIOMA

Detalles del estudio

  • Phase 2

    Fase

  • Géneros

  • 40+

    Rango de edad

  • 52

    Ubicación (es)

  • Not Yet Recruiting

Opciones de tratamiento

Brazos del estudio
INTERVENCIÓN ASIGNADA
Active Comparator: Active Comparator
Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 A
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 B
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 C
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 D
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 E
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 F
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 G
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin
Experimental: BMS-986177 H
Drug: BMS-986177 Other: BMS-986177 Placebo Drug: Clopidogrel Drug: Aspirin

Criterios clave de elegibilidad

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Male and Female ≥40 years of age - Acute Ischemic Stroke or Transient Ischemic Attack - Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain area Exclusion Criteria: - Predicted inability to swallow study medication - Any condition that, in the opinion of the Investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding - Use of thrombolytic therapy or mechanical thrombectomy for treatment of acute ischemic stroke event Other protocol defined inclusion/exclusion criteria could apply

¿Tiene alguna pregunta? Llame 855-907-3286 o Envíenos un correo electrónico

¿Tiene alguna pregunta?
Llame 855-907-3286 o Envíenos un correo electrónico